Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

U.S. agencies to monitor drinking water for microplastics, pharmaceuticals

April 03, 2026 4 min read Environment & Ecology Science & Technology GS3 (Environment Science & Technology)
On This Page ▼

What Happened

  • The U.S. Environmental Protection Agency (EPA) published a draft Sixth Contaminant Candidate List (CCL 6) that, for the first time, includes microplastics and pharmaceuticals as contaminant groups to be monitored in public drinking water.
  • The draft list also includes PFAS (per- and polyfluoroalkyl substances), disinfection byproducts, 75 individual chemicals, and nine microbes.
  • A 60-day public comment period has been opened; EPA will consult its Science Advisory Board before finalising the list, which is expected to be signed by November 2026.
  • The U.S. Department of Health and Human Services (HHS) concurrently announced a $144 million programme to study the effects of microplastics on the human body.
  • This move does not immediately regulate these substances but initiates a formal research and monitoring process that can lead to binding drinking water standards.

Static Topic Bridges

Contaminant Candidate List (CCL) Under the Safe Drinking Water Act

The U.S. Safe Drinking Water Act (SDWA), 1974, requires the EPA to publish a Contaminant Candidate List every five years — a roster of unregulated substances known or anticipated to occur in public water systems and which may warrant future regulation. Inclusion on the CCL does not create an immediate legal standard; instead, it triggers mandatory monitoring, research funding, and a formal regulatory determination process. EPA must decide whether to regulate at least five contaminants from each CCL. To promulgate a drinking water standard, EPA must demonstrate that a contaminant has adverse health effects, occurs at concentrations of public health concern in water systems, and that regulation would meaningfully reduce risk.

  • CCL 1 was published in 1998; CCL 6 (draft 2026) is the latest iteration.
  • The Unregulated Contaminant Monitoring Rule (UCMR), issued alongside CCL, requires water utilities to monitor up to 30 unregulated contaminants every five years.
  • National Primary Drinking Water Regulations (NPDWRs) set enforceable maximum contaminant levels (MCLs); CCL listing is a prerequisite for that process.
  • PFAS were the subject of the first-ever binding MCL under SDWA in 2024, demonstrating the pathway from CCL listing to regulation.

Connection to this news: Placing microplastics and pharmaceuticals on CCL 6 is the first formal step toward potential binding drinking water standards for these substances in the U.S., making the process highly relevant as a governance model studied globally.

Microplastics — Sources, Pathways, and Health Concerns

Microplastics are plastic particles smaller than 5 mm, generated through the fragmentation of larger plastic products or manufactured as microbeads for cosmetics and industrial use. They enter water bodies through surface runoff, wastewater treatment plant effluent (which cannot fully filter them), and atmospheric deposition. In drinking water, they have been detected at concentrations ranging from a few to thousands of particles per litre in both tap and bottled water globally. Health concerns include potential endocrine disruption, inflammation, and carriage of persistent organic pollutants and heavy metals adsorbed onto plastic surfaces. The WHO flagged microplastics in drinking water as a priority concern in its 2019 review, calling for accelerated research.

  • India generates approximately 3.4 million tonnes of plastic waste annually; rivers including the Ganga carry significant microplastic loads.
  • The Central Pollution Control Board (CPCB) has not yet established enforceable standards for microplastics in Indian drinking water.
  • Nanoplastics (< 1 µm) are considered even more hazardous because they can cross biological membranes, including the blood-brain barrier.
  • The 2022 Stockholm Convention review process has considered listing certain microplastic-generating polymer additives as persistent organic pollutants.

Connection to this news: The EPA's CCL 6 inclusion of microplastics may accelerate international standard-setting discussions, including in India where regulatory frameworks for emerging water contaminants remain nascent.

Pharmaceuticals as Emerging Water Contaminants

Active pharmaceutical ingredients (APIs) enter water systems through human excretion (drugs are metabolised and excreted), improper disposal of unused medicines, and pharmaceutical manufacturing effluent. Conventional water treatment processes — coagulation, sedimentation, chlorination — are largely ineffective at removing trace pharmaceuticals. Studies have detected antibiotics, hormones (including synthetic oestrogens from contraceptive pills), anti-depressants, and anti-inflammatory drugs in rivers and groundwater across Europe, Asia, and the Americas. The ecological consequences include feminisation of fish populations due to oestrogenic compounds, and the acceleration of antimicrobial resistance (AMR) in aquatic bacteria exposed to sub-lethal antibiotic concentrations.

  • The WHO's AMR Action Plan (2015) and the One Health framework both identify pharmaceutical contamination of water as a key driver of AMR.
  • India is a major global pharmaceutical manufacturer; Hyderabad's Patancheru and Bollaram industrial zones have historically shown extremely high antibiotic concentrations in local waterways.
  • The National Green Tribunal (NGT) has issued directives on zero liquid discharge (ZLD) for pharmaceutical units, though enforcement is uneven.
  • The European Union's revised Urban Wastewater Treatment Directive (2024) introduces extended producer responsibility (EPR) for pharmaceuticals to fund advanced wastewater treatment.

Connection to this news: The EPA's decision to formally monitor pharmaceuticals in drinking water mirrors concerns directly applicable to India, where pharmaceutical pollution of surface and groundwater has been documented extensively.

Key Facts & Data

  • CCL 6 draft includes: microplastics, pharmaceuticals, PFAS, disinfection byproducts, 75 chemicals, 9 microbes.
  • Public comment period: 60 days from Federal Register publication; final list expected by November 17, 2026.
  • HHS announced $144 million to study microplastic effects on the human body.
  • PFAS regulation under SDWA: first binding MCL for six PFAS compounds issued in April 2024.
  • WHO (2019): flagged microplastics in drinking water as a research and regulatory priority.
  • India's annual plastic waste: ~3.4 million tonnes (CPCB estimate).
  • More than 200 pharmaceuticals have been detected in surface water globally in studies since 2000.